For the most recent call for proposals, Pfizer was interested in research projects that fell within the following therapeutic areas:
- Enhance antitumor immune responses alone or in combination with standard of care.
- Enhance immune surveillance (e.g., tumor neoAg recognition).
- Target unique aspects of tumor or TME metabolic activity.
- Exploit vulnerabilities in tumor heterogeneity, senescence or plasticity.
- Promote or enable tumor-selective or -specific drug delivery or targeting.
Inflammation and Immunology
- Regulate tissue-specific immune cell activation or function.
- Exploit immune cell or lineage-specific metabolic pathways.
- Modulate inflammation and/or tissue remodeling and repair in the context of liver fibrosis (nonalcoholic fatty liver disease [NAFLD]/nonalcoholic steatohepatitis [NASH]).
- Promote gut epithelial barrier health and integrity.
- Regulate antigen-specific tolerance induction and/or modulate T regulatory cells.
Cardiovascular and Metabolic Diseases
- Reverse hepatic steatosis associated with NAFLD/NASH.
- Inhibit lipolysis to treat NAFLD/NASH.
- Reverse cachexia experienced by patients with cancer or chronic diseases, such as heart failure, chronic kidney disease and chronic obstructive pulmonary disease.
- Reverse muscle insulin resistance in patients with type 2 diabetes mellitus.
- Improve heart failure by specifically correcting defects in cardiac metabolism.
- Represent novel targets for nonmalignant hematologic indications, including sickle cell disease and complement mediated diseases.
- Address skeletal and cardiac muscle diseases, including Duchenne or Becker muscular dystrophies.
- Treat repeat expansion diseases, including Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and myotonic dystrophy.